FDA Removes Black Box Warnings on Menopause Hormones for 1-in-8 Breast Cancer Risk Group
Updated
Updated · The Conversation · Jul 30
FDA Removes Black Box Warnings on Menopause Hormones for 1-in-8 Breast Cancer Risk Group
3 articles · Updated · The Conversation · Jul 30
Summary
November 2025 marked the FDA’s start of removing black box warnings from menopausal hormone therapy, opening the door to more individualized treatment discussions for breast cancer survivors.
Past caution stemmed largely from the Women’s Health Initiative and the 2003 HABITS trial, but later scrutiny found limits in their older patient populations, early termination and differing hormone formulations.
Key risk signals appear uneven: estrogen-plus-progesterone has drawn more concern, while estrogen alone did not raise breast cancer risk in some data and some follow-up studies found no significant recurrence or death difference.
Breast cancer affects 1 in 8 women over a lifetime, and diagnoses in women under 50 rose 1.4% annually from 2012 to 2021, making menopause treatment decisions more pressing for younger survivors.
The shift does not declare hormone therapy universally safe; it pushes shared risk-benefit decisions based on age, cancer subtype and formulation as precision medicine reshapes survivorship care.